Jonathan Rubin
Overview
Explore the profile of Jonathan Rubin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Childress A, Asubonteng K, Cox G, Earnest J, Hayman K, Yarullina I, et al.
J Child Adolesc Psychopharmacol
. 2025 Feb;
PMID: 40014428
Viloxazine extended-release (VLX-ER) is effective as monotherapy for attention-deficit/hyperactivity disorder (ADHD), and is often tried as an add-on treatment when psychostimulant therapy fails to provide an adequate treatment response. This...
2.
Coleman-Belin J, Rubin J, Boe L, Diwan R, Monge J, Dinh D, et al.
Ann Surg Oncol
. 2025 Feb;
PMID: 39899216
Background: Risk factors associated with developing lymphedema following axillary lymph node dissection (ALND) are well-described in the literature. However, lymphedema diagnosis criteria is arbitrary and can vary between studies. This...
3.
Campbell A, Kuonqui K, Ashokan G, Rubin J, Shin J, Pollack B, et al.
Front Physiol
. 2024 Dec;
15:1510389.
PMID: 39691094
Secondary lymphedema is a common complication following surgical treatment of solid tumors. Although more prevalent in women due to higher breast cancer rates, men also develop lymphedema, often with more...
4.
Graziano F, Amakiri U, Levy J, Shammas R, Rubin J, Boe L, et al.
J Surg Oncol
. 2024 Dec;
PMID: 39635780
Background: Patients undergoing abdominal-based free flap breast reconstruction are at risk for perioperative venous thromboembolism (VTE), but the optimal anticoagulation protocol remains unknown. We hypothesized that a standardized chemoprophylaxis protocol...
5.
Childress A, Cutler A, Adler L, Fry N, Asubonteng K, Maldonado-Cruz Z, et al.
CNS Drugs
. 2024 Oct;
38(11):891-907.
PMID: 39373844
Background And Objective: Viloxazine ER (extended-release capsules; Qelbree) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of attention-deficit/hyperactivity disorder...
6.
Shanthamallu U, Kilpatrick C, Jones A, Rubin J, Saleh A, Barabasi A, et al.
J Mol Diagn
. 2024 Jul;
26(10):917-930.
PMID: 39067570
The potential of precision medicine to transform complex autoimmune disease treatment is often challenged by limited data availability and inadequate sample size when compared with the number of molecular features...
7.
Campbell A, Baik J, Sarker A, Brown S, Park H, Kuonqui K, et al.
J Invest Dermatol
. 2024 Jun;
145(1):85-97.e4.
PMID: 38879154
Breast cancer-related lymphedema (BCRL) is characterized by skin changes, swelling, fibrosis, and recurrent skin infections. Clinical studies have suggested that lymphedema results in skin barrier defects; however, the underlying cellular...
8.
Nasser A, Gomeni R, Ceresoli-Borroni G, Xie L, Busse G, Melyan Z, et al.
J Pharmacokinet Pharmacodyn
. 2024 May;
51(4):395.
PMID: 38816542
No abstract available.
9.
Zvi Y, Tamura S, Rubin J, Seref-Ferlengez Z, Kamara E
J Am Acad Orthop Surg Glob Res Rev
. 2024 May;
8(5).
PMID: 38748497
Introduction: The Kellgren and Lawrence (KL) classification for knee osteoarthritis estimates disease severity. Its utility in predicting patient-reported outcomes (PROs) after primary total knee arthroplasty (pTKA) has been suggested. We...
10.
Nasser A, Gomeni R, Ceresoli-Borroni G, Xie L, Busse G, Melyan Z, et al.
J Pharmacokinet Pharmacodyn
. 2024 Apr;
51(4):385-393.
PMID: 38578533
The objective of this study was to compare the effectiveness of subcutaneous (SC) and sublingual (SL) formulations of apomorphine for the treatment of motor fluctuations in Parkinson's disease using a...